Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga, Teemu T. Junttila, Klára Tótpál, T. Noelle Lombana, Jennifer Johnston, Amy L. Shelton(Impact Assessment), Elaine Mai(Snap (United States)), Maria Hristopoulos, Robyn Clark, Christoph Spiess(Genentech), Diego Ellerman(Gene Therapy Laboratory), Genee Lee, Kapil Gadkar(Sea Turtle Conservancy), James T. Koerber(Genesys (United States)), Rodney A. Prell, Ji Li, Rajesh Vij(Genentech)
Cited by 141
Related Papers
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267